DaVita Inc. (NYSE:DVA) Position Boosted by Janus Henderson Group PLC

Janus Henderson Group PLC raised its position in shares of DaVita Inc. (NYSE:DVA) by 8.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,847 shares of the company’s stock after buying an additional 457 shares during the quarter. Janus Henderson Group PLC’s holdings in DaVita were worth $958,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of DVA. ORG Partners LLC acquired a new stake in shares of DaVita during the 2nd quarter valued at approximately $82,000. Assenagon Asset Management S.A. lifted its position in shares of DaVita by 29.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company’s stock worth $6,942,000 after buying an additional 11,454 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after buying an additional 78 shares during the period. Chapin Davis Inc. bought a new stake in shares of DaVita during the 2nd quarter valued at about $2,228,000. Finally, Nisa Investment Advisors LLC raised its stake in DaVita by 26.8% during the second quarter. Nisa Investment Advisors LLC now owns 36,694 shares of the company’s stock worth $5,085,000 after acquiring an additional 7,752 shares during the period. Institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. The trade was a 5.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.00% of the company’s stock.

DaVita Price Performance

Shares of NYSE:DVA opened at $152.71 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The firm’s 50 day moving average is $157.94 and its two-hundred day moving average is $150.78. The firm has a market capitalization of $12.52 billion, a P/E ratio of 16.47, a PEG ratio of 0.88 and a beta of 0.90. DaVita Inc. has a 52 week low of $103.40 and a 52 week high of $169.51.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same quarter in the prior year, the business earned $2.85 earnings per share. The firm’s revenue was up 4.6% compared to the same quarter last year. Analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on DVA shares. Truist Financial lifted their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Barclays boosted their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, DaVita presently has an average rating of “Hold” and an average target price of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.